12:00 AM
 | 
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Solzira: Completed Phase II enrollment

Astellas completed enrollment of 474 patients in a double-blind, Japanese Phase II trial comparing oral XP13512 vs. placebo. XenoPort granted GSK rights to the product outside...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >